PD-L1 aAPC Cell
|The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.|
|Stability:||32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)|
|Freeze Medium:||90% FBS+10% DMSO|
|Culture Medium:||RPMI-1640+10%FBS+1ug/ml puromycin+200ug/ml hygromycin|
|Application(s):||Functional(Report Gene) Assay|
|III. Representative Data|
Figure 1. Dose Response of Blocking Antibodies in PD-1/OX40 Dual Effector Reporter Cells (C22) With PD-L1 aAPC Cells.
Figure 2.Dose Response of Blocking Antibodies in PD-1/41BB Dual Effector Reporter Cells (C64) With PD-L1 aAPC Cells.
邮箱： firstname.lastname@example.org （销售部） email@example.com （技术部）